Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
Go back to Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations| (NASDAQ: PVLA) | Delayed: 150.56 -3.76 (2.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $154.32 | 52 Week High | $ | |||
| Open | $154.72 | 52 Week Low | $ | |||
| Day High | $154.72 | P/E | N/A | |||
| Day Low | $149.20 | EPS | $ | |||
| Volume | 646,465 | |||||
